| Identification | Back Directory | [Name]
ST 2825 | [CAS]
894787-30-5 | [Synonyms]
ST 2825
ST 2825;ST2825
(2R,4'R,8'aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxospiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide
Spiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide, 1-[2-[4-[[2-(2,4-dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxo-, (2R,4'R,8'aR)- | [Molecular Formula]
C27H28Cl2N4O5S | [MDL Number]
MFCD30207830 | [MOL File]
894787-30-5.mol | [Molecular Weight]
591.51 |
| Chemical Properties | Back Directory | [Boiling point ]
939.0±65.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
Soluble in DMSO | [form ]
solid | [pka]
12.86±0.70(Predicted) | [color ]
White to off-white | [InChIKey]
HBLHLJXFIPCEMW-ZJSFPPFMSA-N | [SMILES]
N1(C(CC2=CC=C(NC(COC3=CC=C(Cl)C=C3Cl)=O)C=C2)=O)CCC[C@]21C(=O)N1[C@@H](C(N)=O)CCS[C@]1([H])C2 |
| Hazard Information | Back Directory | [Uses]
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity[1][2]. | [Biological Activity]
st 2825 is a specific inhibitor of myd88 dimerization [1].st 2825 is a synthetic compound which mimics the structure of the heptapeptide in the bb-loop of the myd88-tir domain and interferes the homodimerization of myd88. st 2825 was proved to specifically inhibit the homodimerization of myd88 tir domains without affecting the homodimerization of death domains. in hek293t cells transfected with flag-myd88 and myc-myd88, st 2825 inhibited the interaction of the two myd88 by 80% at the concentration of 10 μm. this inhibition resulted in the subsequent interference of the irak1 and irak4 recruitment. besides that, administration of st 2825 significantly inhibited the il-6 production stimulated by il-1β at doses of 100 and 200 mg/kg in mice. furthermore, 8 μm st 2825 completely blocked the tlr9-induced b cell proliferation. st2825 also suppressed the generation of plasma cells induced by cpg dose-dependently [1]. | [in vivo]
ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg[1]. | [target]
MyD88 | [References]
[1] loiarro m, capolunghi f, fantò n, et al. pivotal advance: inhibition of myd88 dimerization and recruitment of irak1 and irak4 by a novel peptidomimetic compound. journal of leukocyte biology, 2007, 82(4): 801-810. |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|